A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"

12 p.

Autores:: Lopez-Jaramillo, Patricio
Pradilla, Lina P.
Lahera, Vicente
Silva Sieger, Federico Arturo
Rueda Clausen, Christian F.
Márquez, Gustavo

Tipo de recurso:: Article of journal

Fecha de publicación:: 2006

Institución:: Universidad de Santander

Repositorio:: Repositorio Universidad de Santander

Idioma:: eng

id	RUDES2_75ac87ffb6fe80e0153a53947972500d
oai_identifier_str	oai:repositorio.udes.edu.co:001/3296
network_acronym_str	RUDES2
network_name_str	Repositorio Universidad de Santander
repository_id_str
dc.title.eng.fl_str_mv	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
title	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
spellingShingle	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA" Candesartan Insulin sensitivity Hypertense subjects Dysglyce mia Abdominal obesity. ARAMIA
title_short	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
title_full	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
title_fullStr	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
title_full_unstemmed	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
title_sort	A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"
dc.creator.fl_str_mv	Lopez-Jaramillo, Patricio Pradilla, Lina P. Lahera, Vicente Silva Sieger, Federico Arturo Rueda Clausen, Christian F. Márquez, Gustavo
dc.contributor.author.spa.fl_str_mv	Lopez-Jaramillo, Patricio Pradilla, Lina P. Lahera, Vicente Silva Sieger, Federico Arturo Rueda Clausen, Christian F. Márquez, Gustavo
dc.subject.proposal.eng.fl_str_mv	Candesartan Insulin sensitivity Hypertense subjects Dysglyce mia Abdominal obesity. ARAMIA
topic	Candesartan Insulin sensitivity Hypertense subjects Dysglyce mia Abdominal obesity. ARAMIA
description	12 p.
publishDate	2006
dc.date.issued.spa.fl_str_mv	2006-09-07
dc.date.accessioned.spa.fl_str_mv	2019-07-08T14:01:48Z
dc.date.available.spa.fl_str_mv	2019-07-08T14:01:48Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.spa.fl_str_mv	10.1186/1745-6215-7-28
dc.identifier.isbn.spa.fl_str_mv	1745-6215
dc.identifier.uri.spa.fl_str_mv	https://repositorio.udes.edu.co/handle/001/3296
identifier_str_mv	10.1186/1745-6215-7-28 1745-6215
url	https://repositorio.udes.edu.co/handle/001/3296
dc.language.iso.spa.fl_str_mv	eng
language	eng
dc.relation.ispartof.eng.fl_str_mv	Trials
dc.rights.spa.fl_str_mv	Derechos Reservados - Trials, 2007
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_f1cf
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/embargoedAccess
dc.rights.creativecommons.spa.fl_str_mv	Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc/4.0/
rights_invalid_str_mv	Derechos Reservados - Trials, 2007 Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_f1cf
eu_rights_str_mv	embargoedAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.source.eng.fl_str_mv	https://trialsjournal.biomedcentral.com/track/pdf/10.1186/1745-6215-7-28
institution	Universidad de Santander
bitstream.url.fl_str_mv	https://repositorio.udes.edu.co/bitstreams/10db1913-5b6a-4e36-a3a5-3c18aca8547b/download https://repositorio.udes.edu.co/bitstreams/39a61069-cb64-411e-ac3c-5ebaa1b00951/download https://repositorio.udes.edu.co/bitstreams/5d649572-c1c2-480e-a2f7-2ad9a112bd75/download https://repositorio.udes.edu.co/bitstreams/2ba1bbf8-5129-4cfc-9915-013560628375/download https://repositorio.udes.edu.co/bitstreams/4c509bc6-4159-4b0d-8544-560f6dd42906/download https://repositorio.udes.edu.co/bitstreams/ee141b84-7413-4e2b-84f3-1e12afeaaf39/download
bitstream.checksum.fl_str_mv	dca0fcc1b4bd1b41d01501e41b064b3c 280060fec3d610a66741f740bdc8e8e6 38d94cf55aa1bf2dac1a736ac45c881c a2f7cf7374d28ad23b911e274b2fde80 ce17bbb4d4f1cbe9a2413e4ea88bb0b2 45916b2f6e55f3b9a47cbd37672d4756
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Universidad de Santander
repository.mail.fl_str_mv	soporte@metabiblioteca.com
_version_	1814158592354287616
spelling	Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Pradilla, Lina P.e62f411c-2c42-4252-b4bb-a9a124b06de9-1Lahera, Vicente06613d10-690d-4af8-8766-1d1474e0d045-1Silva Sieger, Federico Arturo9cced475-6773-4f4f-b4e7-bbebe82a3e16-1Rueda Clausen, Christian F.bb29e148-b8c5-43f2-9fc0-4eeebb36706b-1Márquez, Gustavod488de8a-8f36-4b12-8dea-eeb0bf1de121-12019-07-08T14:01:48Z2019-07-08T14:01:48Z2006-09-0712 p.Background: The raising prevalence of type-2 diabetes mellitus and obesity has been recognized as a major problem for public health, affecting both developed and developing countries. Impaired fasting plasma glucose has been previously associated with endothelial dysfunction, higher levels of inflammatory markers and increased risk of developing insulin resistance and cardiovascular events. Besides life-style changes, the blockade of the renin-angiotensin system has been proposed as a useful alternative intervention to improve insulin resistance and decrease the number of new type-2 diabetes cases. The aim of this clinical trial is to study the effect of the treatment with Candesartan, an angiotensin II receptor antagonist, on the insulin resistance, the plasma levels of adipoquines, oxidative stress and prothrombotic markers, in a group of non diabetic, non hypertensive, dysglycemic and obese subjects. Methods and design: A randomized, double blind, cross-over, placebo-controlled, clinical trial was designed to assess the effects of Candesartan (up to 32 mg/day during 6 months) on the Homeostasis Model Assessment (HOMA) index, lipid profile, protrombotic state, oxidative stress and plasma levels of inflammatory markers. The participants will be recruited in the "Fundación Cardiovascular de Colombia". Subjects who fullfil selection criteria will receive permanent educational, nutritional and exercise support during their participation in the study. After a 15 days-run-in period with placebo and life-style recommendations, the patients who have a treatment compliance equal or greater than 80% will be randomlly assigned to one of the treatment groups. Group A will receive Candesartan during 6 months and placebo during 6 months. Group B will receive placebo during the first 6 months, and then, Candesartan during the last 6 months.Control visits will be programed monthly and all parameters of interest will be evaluated every 6 months. Hypothesis: Treatment with Candesartan, could improve the HOMA index, the response to the oral glucose tolerance test and reduce the plasma levels of adipoquines, oxidative stress and prothrombotic markers, in non diabetic, non hypertense subjects with dysglycemia and abdominal obesity, recruited from a population at high risk of developing insulin resistance. These effects are independent of the changes in arterial blood pressure. Trial registration: NCT00319202.application/pdf10.1186/1745-6215-7-281745-6215https://repositorio.udes.edu.co/handle/001/3296engTrialsDerechos Reservados - Trials, 2007info:eu-repo/semantics/embargoedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_f1cfhttps://trialsjournal.biomedcentral.com/track/pdf/10.1186/1745-6215-7-28CandesartanInsulin sensitivityHypertense subjectsDysglyce miaAbdominal obesity.ARAMIAA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"Artículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85PublicationTHUMBNAILA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdomin.pdf.jpgA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdomin.pdf.jpgGenerated Thumbnailimage/jpeg1607https://repositorio.udes.edu.co/bitstreams/10db1913-5b6a-4e36-a3a5-3c18aca8547b/downloaddca0fcc1b4bd1b41d01501e41b064b3cMD57A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesi.pdf.jpgA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesi.pdf.jpgGenerated Thumbnailimage/jpeg16321https://repositorio.udes.edu.co/bitstreams/39a61069-cb64-411e-ac3c-5ebaa1b00951/download280060fec3d610a66741f740bdc8e8e6MD510LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/5d649572-c1c2-480e-a2f7-2ad9a112bd75/download38d94cf55aa1bf2dac1a736ac45c881cMD52ORIGINALA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesi.pdfArtículo Principalapplication/pdf967817https://repositorio.udes.edu.co/bitstreams/2ba1bbf8-5129-4cfc-9915-013560628375/downloada2f7cf7374d28ad23b911e274b2fde80MD58TEXTA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdomin.pdf.txtA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdomin.pdf.txtExtracted texttext/plain4https://repositorio.udes.edu.co/bitstreams/4c509bc6-4159-4b0d-8544-560f6dd42906/downloadce17bbb4d4f1cbe9a2413e4ea88bb0b2MD56A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesi.pdf.txtA randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesi.pdf.txtExtracted texttext/plain73051https://repositorio.udes.edu.co/bitstreams/ee141b84-7413-4e2b-84f3-1e12afeaaf39/download45916b2f6e55f3b9a47cbd37672d4756MD59001/3296oai:repositorio.udes.edu.co:001/32962023-10-10 09:04:16.371https://creativecommons.org/licenses/by-nc/4.0/Derechos Reservados - Trials, 2007https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo=

A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity. "ARAMIA"

Publicaciones similares